Bristol-Myers Squibb (BMY) Q1 2012 Earnings Call April 26, 2012 10:30 am ET Executives John Elicker - Investor Relations Executive Lamberto Andreotti - Chief Executive Officer, Director, Member of Executive Committee and Member of Science & Technology Committee Charles A. Bancroft - Chief Financial Officer and Executive Vice President
Elliott Sigal - Chief Scientific Officer, President of Research & Development, Executive Vice President, Director, Member of Executive Committee and Member of Science & Technology Committee Giovanni Caforio - President of U.S. Pharmaceuticals Beatrice Cazala - Executive Vice President of Commercial Operations Analysts Jami Rubin - Goldman Sachs Group Inc., Research Division Alison Yang - Barclays Capital, Research Division Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division Seamus Fernandez - Leerink Swann LLC, Research Division Christopher Schott - JP Morgan Chase & Co, Research Division Mark J. Schoenebaum - ISI Group Inc., Research Division Gregory B. Gilbert - BofA Merrill Lynch, Research Division Marc Goodman - UBS Investment Bank, Research Division John T. Boris - Citigroup Inc, Research Division David Risinger - Morgan Stanley, Research Division PresentationOperator Ladies and gentlemen, please standby. We are about to begin. Good day, everyone, and welcome to today's First Quarter 2012 Earnings Release Conference Call. The call is being recorded. And now, your host for today's call, Mr. John Elicker, Senior Vice President of Investor Relations and Public affairs. Mr. Elicker, please go ahead, sir. John Elicker Thanks, Rufus, and good morning, everybody. Thanks for joining us to review our Q1 results. With me this morning are Lamberto Andreotti, our Chief Executive Officer; and Charlie Bancroft, our Chief Financial Officer. They'll both have prepared remarks. And joining us for Q&A are Elliott Sigal, our Head of R&D; Beatrice Cazala, Commercial Operations; and Giovanni Caforio who runs our U.S. business.